Vilazodone Hydrochloride-Loaded Nanostructured Lipid Carrier In Situ Gel for Intranasal Nose-to-Brain Antidepressant Delivery

News aggregator

17 Oct 2026 0 comments

The Oral delivery of vilazodone hydrochloride (VLZ), a serotonin partial agonist-reuptake inhibitor for major depressive disorder, suffers from extensive hepatic first-pass metabolism, food-dependent absorption, and poor blood-brain barrier (BBB) penetration, limiting its central therapeutic impact. Here, VLZ-loaded nanostructured lipid carriers (NLCs) were engineered and embedded within a Poloxamer 407/188-chitosan thermosensitive in situ gel to enable direct nose-to-brain delivery. The NLCs...